X0306 4 2020-02-14 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001230708 STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior Vice President and CFO Emp. Stock Option (Right to Buy) 11.13 2020-02-14 4 A 0 31500 0 A 2020-02-14 2024-12-22 Common Stock 31500 31500 D On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. /s/ Alane P. Barnes, by power of attorney 2020-02-19